Workflow
Contract Research and Manufacturing
icon
Search documents
WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year
Prnewswireยท 2025-09-23 04:00
Core Insights - WuXi Biologics has been recognized as a constituent company of the FTSE4Good Index Series for the fifth consecutive year, highlighting its commitment to sustainability [1] Company Performance - The recognition by FTSE Russell reflects WuXi Biologics' outstanding sustainability performance, reinforcing its position as a leading global Contract Research, Development, and Manufacturing Organization (CRDMO) [1]